7 BD HAUSSMANN, PARIS, I0
Announces Financial Results for the Three and Six Months Ended June 30, 2026
Enters Into Underwriting Agreement for Public Offering of 6,400,000 American Depositary Shares
Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Annouces Results of its May 11, 2026 Annual General Meeting
Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Annual Ordinary and Extraordinary General Meeting of May 11, 2026
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Registration Statement for Depositary Shares, Issued upon Effectiveness
Free Writing Prospectus
Automatic Shelf Registration Statement
Prospectus filed pursuant to Rule 424(b)(7)